Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is the Immune System?01:38

What is the Immune System?

127.2K
Overview
127.2K
Humoral Immune Responses01:36

Humoral Immune Responses

83.5K
Overview
83.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

276
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
276
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

200
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
200
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

261
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
261

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype.

The Journal of clinical investigation·2026
Same author

Cefepime pharmacokinetics in critically ill children with multiple organ dysfunction syndrome using volumetric absorptive microsampling.

Antimicrobial agents and chemotherapy·2026
Same author

Anti-PD-L1 therapy to prevent systemic immune suppression after polytraumatic brain injury in rats.

The journal of trauma and acute care surgery·2026
Same author

A study within a trial evaluating supplemental, reinforced risk-based training to reduce implementation barriers in a pediatric multicenter randomized controlled trial.

Contemporary clinical trials·2026
Same authorSame journal

Drug Administration Patterns in Patients on Extracorporeal Membrane Oxygenation.

Journal of pediatric intensive care·2026
Same author

Real-World Tocilizumab Use in Pediatric Inpatients.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2025
Same journal

Post-Intensive Care Syndrome in a Cohort of School-Aged Children and Adolescent ICU Survivors: The Importance of Follow-up in the Acute Recovery Phase.

Journal of pediatric intensive care·2025
Same journal

Retraction Note: The Effects of Quran Recitation on Sedation and Pain in Children.

Journal of pediatric intensive care·2024
Same journal

Severe Traumatic Brain Injury in French-Speaking Pediatric Intensive Care Units: Study of Practices.

Journal of pediatric intensive care·2024
Same journal

Simulation-Facilitated Education for Pediatric Critical Care Nurse Practitioners' Airway Management Skills: A 10-Year Experience.

Journal of pediatric intensive care·2024
Same journal

A Meta-analysis of the Utility of Red Cell Distribution Width as a Biomarker to Predict Outcomes in Pediatric Illness (PROSPERO CRD42020208777).

Journal of pediatric intensive care·2024
See all related articles

Related Experiment Video

Updated: Jan 25, 2026

A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

486

Immune Modulation in Pediatric Sepsis.

Mark W Hall1,2

  • 1Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States.

Journal of Pediatric Intensive Care
|May 11, 2019
PubMed
Summary
This summary is machine-generated.

Sepsis in children can cause immune suppression, known as immunoparalysis. Immunostimulatory therapies like granulocyte macrophage colony-stimulating factor (GM-CSF) show promise for treating this condition.

Keywords:
TNF αHLA-DRimmunemodulationpediatricsepsis

More Related Videos

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

11.8K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.9K

Related Experiment Videos

Last Updated: Jan 25, 2026

A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

486
A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

11.8K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.9K

Area of Science:

  • Pediatric immunology
  • Critical care medicine
  • Infectious diseases

Background:

  • Sepsis in children initially triggers a proinflammatory response, followed by a counteracting anti-inflammatory response.
  • Severe anti-inflammatory response in sepsis leads to immunoparalysis, characterized by hyporesponsiveness of immune cells.
  • Immunoparalysis is linked to prolonged organ dysfunction, increased nosocomial infections, and mortality in pediatric sepsis.

Purpose of the Study:

  • To review the characteristics of sepsis-induced immune suppression in children.
  • To explore the potential of immunostimulatory therapies for sepsis-induced immunoparalysis.
  • To highlight the need for immunophenotype-specific clinical trials in pediatric sepsis.

Main Methods:

  • Review of existing literature on pediatric sepsis and immune responses.
  • Discussion of laboratory markers for sepsis-induced immune suppression (e.g., cytokine production, HLA-DR expression).
  • Analysis of the efficacy of anti-inflammatory versus immunostimulatory therapies.

Main Results:

  • Sepsis-induced immune suppression in children is marked by reduced cytokine production, decreased HLA-DR expression on monocytes, and lower cell counts.
  • Anti-inflammatory therapies have shown limited success in improving sepsis outcomes.
  • Immunostimulatory therapies, such as GM-CSF, demonstrate potential in managing sepsis-induced immunoparalysis.

Conclusions:

  • Understanding risk factors for immunoparalysis is crucial for improving outcomes in pediatric sepsis.
  • Further research and immunophenotype-specific clinical trials are necessary to optimize immune function strategies.
  • Targeted immunostimulatory approaches may offer a promising avenue for treating sepsis-induced immune suppression in children.